HUP0400528A2 - Use of neuropeptidaz inhibitor for preparation of pharmaceutical conposition suitable for treatment of male sexual dysfunction - Google Patents
Use of neuropeptidaz inhibitor for preparation of pharmaceutical conposition suitable for treatment of male sexual dysfunctionInfo
- Publication number
- HUP0400528A2 HUP0400528A2 HU0400528A HUP0400528A HUP0400528A2 HU P0400528 A2 HUP0400528 A2 HU P0400528A2 HU 0400528 A HU0400528 A HU 0400528A HU P0400528 A HUP0400528 A HU P0400528A HU P0400528 A2 HUP0400528 A2 HU P0400528A2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitor
- preparation
- treatment
- neuropeptidaz
- sexual dysfunction
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 206010057672 Male sexual dysfunction Diseases 0.000 title 1
- 101710151321 Melanostatin Proteins 0.000 abstract 3
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 3
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 210000000260 male genitalia Anatomy 0.000 abstract 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/344—Disorders of the penis and the scrotum and erectile dysfuncrion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A találmány tárgya neuropeptid Y (NPY) inhibitor, előnyösen NPY Y'-receptor-inhibitor - amely szelektív hím genitáliákkal asszociált NPY-vagy NPY Y'-receptorokra -, alkalmazása férfi erekciós funkciózavar(<male erectile dysfunction<; MED) kezelésére vagy megelőzésérealkalmas gyógyszer előállítására/készítésére. ÓThe subject of the invention is a neuropeptide Y (NPY) inhibitor, preferably an NPY Y'-receptor inhibitor - which is selective for NPY or NPY Y'-receptors associated with male genitalia -, the use of which is suitable for the treatment or prevention of male erectile dysfunction (MED) for the production/preparation of medicine. HE
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0030647A GB0030647D0 (en) | 2000-12-15 | 2000-12-15 | Treatment of male sexual dysfunction |
| GB0108730A GB0108730D0 (en) | 2001-04-06 | 2001-04-06 | Treatment of male sexual dysfunction |
| GB0109910A GB0109910D0 (en) | 2001-04-23 | 2001-04-23 | Treatment of sexual dysfunction |
| GB0111037A GB0111037D0 (en) | 2001-05-04 | 2001-05-04 | Treatment of sexual dysfunction |
| US09/895,367 US20020028799A1 (en) | 2000-07-06 | 2001-06-29 | Treatment of male sexual dysfunction |
| US09/905,846 US6878529B2 (en) | 2000-07-14 | 2001-07-13 | Compounds for the treatment of sexual dysfunction |
| GB0120679A GB0120679D0 (en) | 2001-08-24 | 2001-08-24 | Treatment of male sexual dysfunction |
| PCT/IB2001/002399 WO2002047670A1 (en) | 2000-12-15 | 2001-12-10 | Treatment of male sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0400528A2 true HUP0400528A2 (en) | 2004-06-28 |
Family
ID=27562581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0400528A HUP0400528A2 (en) | 2000-12-15 | 2001-12-10 | Use of neuropeptidaz inhibitor for preparation of pharmaceutical conposition suitable for treatment of male sexual dysfunction |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1347750A1 (en) |
| JP (1) | JP2004522720A (en) |
| CN (1) | CN1496254A (en) |
| AU (1) | AU2002220977A1 (en) |
| CA (1) | CA2431747A1 (en) |
| HU (1) | HUP0400528A2 (en) |
| IL (1) | IL155775A0 (en) |
| NZ (1) | NZ526925A (en) |
| WO (1) | WO2002047670A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149416A0 (en) | 1999-11-19 | 2002-11-10 | Solvay Pharm Bv | Human enzymes of the metalloprotease family |
| AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
| WO2005000217A2 (en) * | 2003-06-06 | 2005-01-06 | Merck & Co., Inc. | Combination therapy for the treatment of dyslipidemia |
| EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| WO2009052376A1 (en) | 2007-10-18 | 2009-04-23 | Musc Foundation For Research Development | Methods for the diagnosis of genitourinary cancer |
| DE102009018668A1 (en) | 2009-04-23 | 2010-11-25 | Igor Lier | Folding shower cubicle is provided with fixed, but foldable side walls and wide entry door, where shower tray is folded into folding unit |
| AU2011330757B2 (en) * | 2010-11-15 | 2016-05-26 | Neuroderm Ltd | Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same |
| CN111840508A (en) * | 2020-07-17 | 2020-10-30 | 北京清大赛尔生物科技有限公司 | External preparation for preventing and treating male sexual dysfunction and application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7580998A (en) * | 1997-05-21 | 1998-12-11 | Eli Lilly And Company | 3-arylpropylamino neuropeptide y receptor antagonists |
| IL139456A0 (en) * | 1999-11-08 | 2001-11-25 | Pfizer | Compounds for the treatment of female sexual dysfunction |
| AU4929601A (en) * | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
| US6444675B2 (en) * | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
| US6479482B2 (en) * | 2000-05-10 | 2002-11-12 | Bristol-Myers Squibb Company | Alkylamine derivatives of dihydropyridine NPY antagonists |
| US6432960B2 (en) * | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
-
2001
- 2001-12-10 EP EP01270206A patent/EP1347750A1/en not_active Withdrawn
- 2001-12-10 JP JP2002549244A patent/JP2004522720A/en not_active Withdrawn
- 2001-12-10 HU HU0400528A patent/HUP0400528A2/en unknown
- 2001-12-10 AU AU2002220977A patent/AU2002220977A1/en not_active Abandoned
- 2001-12-10 NZ NZ526925A patent/NZ526925A/en unknown
- 2001-12-10 CA CA002431747A patent/CA2431747A1/en not_active Abandoned
- 2001-12-10 WO PCT/IB2001/002399 patent/WO2002047670A1/en not_active Application Discontinuation
- 2001-12-10 CN CNA018205569A patent/CN1496254A/en active Pending
- 2001-12-10 IL IL15577501A patent/IL155775A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002220977A1 (en) | 2002-06-24 |
| IL155775A0 (en) | 2003-12-23 |
| CN1496254A (en) | 2004-05-12 |
| CA2431747A1 (en) | 2002-06-20 |
| EP1347750A1 (en) | 2003-10-01 |
| JP2004522720A (en) | 2004-07-29 |
| NZ526925A (en) | 2005-03-24 |
| WO2002047670A1 (en) | 2002-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL157320A0 (en) | Rapid-onset medicament for the treatment of sexual dysfunction | |
| MXPA04003668A (en) | Type 4 phosphodiesterase inhibitors and uses thereof. | |
| WO2004005324A3 (en) | Peptide composition for treatment of sexual dysfunction | |
| MY127290A (en) | New use of flibanserin | |
| GB0223040D0 (en) | Therapeutic compounds | |
| BR0316753A (en) | Treatment method for sexual dysfunction | |
| AP2001002125A0 (en) | Controlled-rease pharmaceutical formulations. | |
| CL2004000192A1 (en) | USE OF COMPOUNDS DERIVED FROM 2-AMINOPIRIMIDINE TO PREPARE A MEDICINAL PRODUCT FOR THE PREVENTION OF HIV INFECTION SEXUAL RELATIONS OR AN INTIMATE COUPLE CONTACT. | |
| HUP0401811A2 (en) | Medicinal composition improved in solubility in water and process for its preparation | |
| NO20035025L (en) | Use of osteopontin for the treatment and / or prevention of neurological diseases, as well as a pharmaceutical composition comprising osteopontin or an antagonist with osteopontin activity. | |
| HUP0400648A2 (en) | Compositions for antitumour treatment containing ecteinascidin 743 | |
| NO20023962D0 (en) | Use of IL-18 inhibitors | |
| BRPI0513051A (en) | combination of reverse transcriptase inhibitors and anti-HIV protease | |
| HUP0202687A2 (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
| NO20042208L (en) | Vaginally administered anti-dysrhythmic agents for the treatment of pelvic pain | |
| SE0101932D0 (en) | Pharmaceutical combinations | |
| ATE357438T1 (en) | 1,2,4-TRIAMINOBENZENE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | |
| HUP0400528A2 (en) | Use of neuropeptidaz inhibitor for preparation of pharmaceutical conposition suitable for treatment of male sexual dysfunction | |
| NZ530587A (en) | Diazacycloalkanes as oxytocin agonists | |
| TR200302134T4 (en) | Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or physiologically acceptable salts thereof as anti-cancer agents. | |
| HUP0302738A2 (en) | Use of sarp-1 for the treatment and/or prevention of scleroderma | |
| HK1065305A1 (en) | Substituted 4-aminocyclohexanol derivatives | |
| HUP0303181A2 (en) | Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions suitable for treating of myocardial diseases | |
| WO2003000269A3 (en) | Novel use for pde 10a inhibitors | |
| NO20033634L (en) | GlyT1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |